Abstract:Background In people with multiple sclerosis (pwMS), muscle fatigue and weakness are common issues that can interfere with daily activities. Photobiomodulation therapy (PBMT), comprising light in a 600-1100 nm bandwidth, is a low-level laser therapy thought to improve muscle performance in non-disease populations, in part, by improving mitochondrial function and thus, might be beneficial in pwMS. Given this potential, we aimed to investigate the effects of PBMT on muscle performance in pwMS, both in the short-term and over an extended period. Methods This study consisted of two parts with a randomized double-blind crossover design. In study I, muscle function was assessed in four sessions before and after PBMT in ambulatory pwMS (N=17, F=14) as follows: maximal voluntary contraction (MVC) and muscle fatigue of the right tibialis anterior (TA) muscle was compared at baseline and following a two-min submaximal fatiguing contraction. Then, PBMT was administered to the belly of TA muscle at different doses of energy of an active device (40J, 80J, 120J) or placebo. The muscle function assessment was then repeated. Outcome variables: muscle force recovery (%), muscle fatigue (%). Statistical tests included McNemar's exact test, Wilcoxon signed-rank test, and the Friedman test. In study II, a subgroup from study I (N=12, F=11) received individualized doses (i.e., best dose-effect observed in study I) of active, or placebo PBMT, which was administered on the TA muscle for two weeks. Muscle function assessments were performed pre- and post-PBMT in four sessions similar to study I. Outcome variables: Baseline strength (N), endurance time (sec), and muscle fatigue (%). The Wilcoxon signed-rank test was used for statistical analysis. Values are reported as mean (SD). Results In study I, participants who received a high dose of PBMT showed significant improvement in force recovery (101.89% (13.55%)) compared to the placebo group (96.3% (18.48%); p=0.03). Muscle fatigue did not significantly improve with either active PBMT or placebo. In study II, active PBMT resulted in a significant improvement in muscle strength compared to both the baseline (pre-PBMT= 162.70N (37.52N); post-PBMT=185.56N (33.95N); p=0.01) and the placebo group (active PBMT: mean-change=22.87N (23.67N); placebo: mean-change=-4.12N (31.95N); p=0.02). Endurance time and muscle fatigue did not show significant improvement with either active PBMT or placebo. Conclusion Our findings suggest that an individualized dose of PBMT might improve muscle performance, including force recovery and strength in individuals with mild-moderate MS. Therefore, PBMT might be a novel therapeutic modality, either as a standalone treatment or in combination with other interventions, to improve muscle performance in pwMS.

Short-term efficacy of photobiomodulation in early and intermediate age-related macular degeneration: the PBM4AMD study

Multiwavelength photobiomodulation in atrophic age-related macular degeneration

Safety, Tolerability, and Short-Term Efficacy of Low-Level Light Therapy for Dry Age-Related Macular Degeneration

Short term effects of extremely low irradiance photobiomodulation on retinal function, in age related macular degeneration

Photobiomodulation efficacy in age-related macular degeneration: a systematic review and meta-analysis of randomized clinical trials

Efficacy of Photobiomodulation Therapy in Older Adults: A Systematic Review

Photobiomodulation in Ophthalmology: A Comprehensive Review of Bench-to-Bedside Research and Clinical Integration

Comparison of the effects of 2 frequencies of application of photobiomodulation on facial rejuvenation: Controlled, randomized, and double-blind clinical trial

808-nm Photobiomodulation Affects the Viability of a Head and Neck Squamous Carcinoma Cellular Model, Acting on Energy Metabolism and Oxidative Stress Production

Photobiomodulation in the aging brain: a systematic review from animal models to humans

Photobiomodulation use in ophthalmology - an overview of translational research from bench to bedside

Systematic review of photobiomodulation for multiple sclerosis

Retinal pigment epithelium in the pathogenesis of age-related macular degeneration and photobiomodulation as a potential therapy?

Photobiomodulation at Defined Wavelengths Regulates Mitochondrial Membrane Potential and Redox Balance in Skin Fibroblasts

The Therapeutic Effects of Long-term Photobiomodulation on Aging in Mice

Photobiomodulation preserves mitochondrial redox state and is retinoprotective in a rodent model of retinitis pigmentosa

Effects of Short-, Medium-, and Long-Term Treatment Using Photobiomodulation Therapy Combined with Static Magnetic Field in Aging Rats

Photobiomodulation CME Part II: Clinical Applications in Dermatology

Effects of Photobiomodulation Therapy on Muscle Function on Individuals with Multiple Sclerosis

Study and optimization of the photobiomodulation effects induced on mitochondrial metabolic activity of human cardiomyocytes for different radiometric and spectral conditions

Photobiomodulation CME Part I: Overview and Mechanism of Action